Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects With Axillary Hyperhidrosis

Trial Profile

A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects With Axillary Hyperhidrosis

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs Sofpironium bromide (Primary)
  • Indications Hyperhidrosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Cardigan I
  • Sponsors Brickell Biotech
  • Most Recent Events

    • 07 Feb 2019 Status changed from planning to not yet recruiting.
    • 04 Dec 2018 New trial record
    • 19 Nov 2018 According to a Brickell Biotech media release, the company anticipates to initiate this trial in the first half of 2019, and by the second half of 2020 the company intends to have completed all necessary activities required to file a New Drug Application (NDA) with the FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top